The effect of empagliflozin on growth differentiation factor 15 in patients with heart failure: a randomized controlled trial (Empire HF Biomarker)

[1]  L. Rohde,et al.  Growth/differentiation factor-15 (GDF-15) as a predictor of serious arrhythmic events in patients with nonischemic dilated cardiomyopathy. , 2021, Journal of electrocardiology.

[2]  L. Køber,et al.  Metabolic Effects of Empagliflozin in Heart Failure: A Randomized, Double-Blind, and Placebo-Controlled Trial (Empire HF Metabolic). , 2021, Circulation.

[3]  Yufei Wang,et al.  Increased Serum GDF15 Related to Improvement in Metabolism by Lifestyle Intervention Among Young Overweight and Obese Adults , 2021, Diabetes, metabolic syndrome and obesity : targets and therapy.

[4]  P. Ponikowski,et al.  Efficacy and safety of dapagliflozin according to aetiology in heart failure with reduced ejection fraction: insights from the DAPA‐HF trial , 2021, European journal of heart failure.

[5]  L. Køber,et al.  Associations of Empagliflozin With Left Ventricular Volumes, Mass, and Function in Patients With Heart Failure and Reduced Ejection Fraction: A Substudy of the Empire HF Randomized Clinical Trial. , 2021, JAMA cardiology.

[6]  L. Køber,et al.  Effects of empagliflozin on estimated extracellular volume, estimated plasma volume, and measured glomerular filtration rate in patients with heart failure (Empire HF Renal): a prespecified substudy of a double-blind, randomised, placebo-controlled trial. , 2020, The lancet. Diabetes & endocrinology.

[7]  L. Køber,et al.  Effect of Empagliflozin on Hemodynamics in Patients With Heart Failure and Reduced Ejection Fraction. , 2020, Journal of the American College of Cardiology.

[8]  Deepak L. Bhatt,et al.  Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure. , 2020, The New England journal of medicine.

[9]  J. McMurray,et al.  Effect of Empagliflozin on Left Ventricular Volumes in Patients With Type 2 Diabetes, or Prediabetes, and Heart Failure With Reduced Ejection Fraction (SUGAR-DM-HF) , 2020, Circulation.

[10]  P. Ponikowski,et al.  Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure. , 2020, The New England journal of medicine.

[11]  L. Køber,et al.  Twelve weeks of treatment with empagliflozin in patients with heart failure and reduced ejection fraction: A double-blinded, randomized, and placebo-controlled trial. , 2020, American heart journal.

[12]  Stephen A. Williams,et al.  Mechanisms of Sodium–Glucose Cotransporter 2 Inhibition: Insights From Large-Scale Proteomics , 2020, Diabetes Care.

[13]  S. Rabkin,et al.  The utility of growth differentiation factor-15, galectin-3, and sST2 as biomarkers for the diagnosis of heart failure with preserved ejection fraction and compared to heart failure with reduced ejection fraction: a systematic review , 2020, Heart Failure Reviews.

[14]  T. Fall,et al.  GDF-15 is associated×with sudden cardiac death due to incident myocardial infarction. , 2020, Resuscitation.

[15]  Man Li,et al.  Growth differentiation factor-15 is associated with cardiovascular outcomes in patients with coronary artery disease , 2020, Cardiovascular Diabetology.

[16]  Y. Bao,et al.  The association between serum growth differentiation factor 15 levels and lower extremity atherosclerotic disease is independent of body mass index in type 2 diabetes , 2020, Cardiovascular Diabetology.

[17]  I. Pernicova,et al.  Metformin to reduce metabolic complications and inflammation in patients on systemic glucocorticoid therapy: a randomised, double-blind, placebo-controlled, proof-of-concept, phase 2 trial. , 2020, The lancet. Diabetes & endocrinology.

[18]  S. O’Rahilly,et al.  GDF15 mediates the effects of metformin on body weight and energy balance , 2019, Nature.

[19]  Amogelang R. Raphenya,et al.  Metformin-induced increases in GDF15 are important for suppressing appetite and promoting weight loss , 2019, Nature Metabolism.

[20]  Akshay S. Desai,et al.  Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. , 2019, The New England journal of medicine.

[21]  M. Pisani,et al.  GDF15 Is an Inflammation-Induced Central Mediator of Tissue Tolerance , 2019, Cell.

[22]  L. Køber,et al.  Empagliflozin in heart failure patients with reduced ejection fraction: a randomized clinical trial (Empire HF) , 2019, Trials.

[23]  B. Zinman,et al.  Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. , 2019, The New England journal of medicine.

[24]  S. Solomon,et al.  Growth differentiation factor‐15 is not modified by sacubitril/valsartan and is an independent marker of risk in patients with heart failure and reduced ejection fraction: the PARADIGM‐HF trial , 2018, European journal of heart failure.

[25]  A. Sainsbury,et al.  The MIC-1/GDF15-GFRAL Pathway in Energy Homeostasis: Implications for Obesity, Cachexia, and Other Associated Diseases. , 2018, Cell metabolism.

[26]  F. Tacke,et al.  Growth Differentiation Factor-15 Is a Predictor of Mortality in Critically Ill Patients with Sepsis , 2017, Disease markers.

[27]  T. Cash-Mason,et al.  GFRAL is the receptor for GDF15 and the ligand promotes weight loss in mice and nonhuman primates , 2017, Nature Medicine.

[28]  V. Melenovský,et al.  Evidence Supporting the Existence of a Distinct Obese Phenotype of Heart Failure With Preserved Ejection Fraction , 2017, Circulation.

[29]  J. Auwerx,et al.  Growth differentiation factor 15 is a myomitokine governing systemic energy homeostasis , 2017, The Journal of cell biology.

[30]  V. Melenovský,et al.  High-Output Heart Failure: A 15-Year Experience. , 2016, Journal of the American College of Cardiology.

[31]  M. Fischereder,et al.  Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. , 2016, The New England journal of medicine.

[32]  R. Holman,et al.  Metformin for non-diabetic patients with coronary heart disease (the CAMERA study): a randomised controlled trial. , 2014, The lancet. Diabetes & endocrinology.

[33]  S. Jørgensen,et al.  TGF-b Superfamily Cytokine MIC-1/GDF15 Is a Physiological Appetite and Body Weight Regulator , 2013, PloS one.

[34]  A. Khera,et al.  Association of growth differentiation factor-15 with coronary atherosclerosis and mortality in a young, multiethnic population: observations from the Dallas Heart Study. , 2012, Clinical chemistry.

[35]  B. Ludvik,et al.  The relationship between insulin resistance and the cardiovascular biomarker growth differentiation factor-15 in obese patients. , 2011, Clinical chemistry.

[36]  P. Ponikowski,et al.  Prognostic utility of growth differentiation factor-15 in patients with chronic heart failure. , 2007, Journal of the American College of Cardiology.